Severe falciparum malaria — DTM&H MCQ

Correct answer: A — Intravenous artesunate with supportive critical care

The correct answer is A, intravenous artesunate with supportive critical care. This patient meets multiple WHO/UK criteria for severe falciparum malaria: impaired consciousness, hypoglycaemia (2.5 mmol/L), raised lactate (6.1 mmol/L) indicating metabolic acidosis, jaundice, and parasitaemia over 2 percent (here 8 percent). UK malaria treatment guidelines recommend IV artesunate as first-line therapy for severe disease in both adults and children, given its proven mortality benefit over quinine. Management must occur in a critical care or high-dependency setting with correction of hypoglycaemia, monitoring for post-artesunate delayed haemolysis, and infectious diseases input, as parenteral therapy alone is insufficient without full supportive care. Why the other options are wrong: B. Oral chloroquine after parasite speciation: chloroquine has no role in falciparum malaria due to widespread resistance, and speciation is already confirmed on thick film; oral therapy is unsafe in a patient with impaired consciousness and severe disease. E. Intravenous quinine as first-line therapy: quinine is now second-line, reserved for when artesunate is unavailable or contraindicated, as trials show higher mortality than artesunate; it also risks worsening hypoglycaemia through insulin secretagogue effects, dangerous in this patient. D. Atovaquone-proguanil as definitive monotherapy: this is an oral agent for uncomplicated malaria only and cannot be relied upon when severity criteria and reduced conscious level make oral absorption unsafe and unpredictable. C. Oral artemether-lumefantrine with outpatient review: oral ACT is for uncomplicated malaria; outpatient management is contraindicated with organ dysfunction, hypoglycaemia and high parasitaemia, which mandate inpatient parenteral treatment. Key point: Any severity criterion (impaired consciousness, hypoglycaemia, acidosis/raised lactate, jaundice with organ dysfunction, or parasitaemia over 2 percent) mandates IV artesunate and critical care, never oral therapy.

Reference: UK Malaria Treatment Guidelines Writing Group, 'UK malaria treatment guidelines 2016', Journal of Infection (endorsed guidance for UK practice, referenced by UKHSA); https://pmc.ncbi.nlm.nih.gov/articles/PMC7132403/